Bridging Innovators: Wallonia-UK Advanced Therapies Mission 2024

30 Sept – 3 Oct 2024 | United Kingdom

Matthew Cobb

Senior Account Director

Catalent Cell and Gene Therapy

Cambridge UK, United Kingdom

2 profile visits

I work in BD for Catalent CGT for the Gosselies, Belgium site for CDMO activities, associated with cell therapy programs from concept to commercialisation

About

Experienced management professional aiming for long-term development within the field of cell and gene therapy.
Experience in working in the novel field of Immunotherapy for multiple years, and it's immense potential for the treatment of many conditions both now and in the future.
Multiple viewpoints gained from working for a range of companies, from contract clinical research, to manufacturing of ATMPs and biologics, and currently with the present role of clinical sales and management in support of developing companies advanced therapies from concept to commercialisation.
Management experience of both customer accounts and for new members of the clinical team, offering training and support schedules.
Excited to be able to work with many people from various backgrounds and experiences, to learn and share understanding to help develop both parties.
Keen to bring ideas to the table, and hope to make positive changes to impact companies I work for.
Frequently present in front of large audiences for work groups and to customers.
Motivation to succeed and maintain rate of career development throughout entire career to become an expert in field(s) of interest.

My organisation

Catalent Cell & Gene Therapy is an industry-leading Contract Development and Manufacturing Organization (CDMO) for advanced therapeutics. Our comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies, Catalent is a full-service CDMO for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, oncolytic viruses, and live virus vaccines. An experienced and innovative partner, Catalent Cell & Gene Therapy has a global network of dedicated, small- and large-scale clinical and commercial manufacturing facilities, including an FDA-licensed viral vector facility, and fill/finish capabilities located in both the U.S. and Europe.

Social media

Skills

  • cell therapy
  • Commercialisation
  • Process Development
  • gene therapy
  • CAR T
  • Gene-modified stem cells
  • NK cells
  • Antigen-specific T-cells
  • Macrophages
  • Dendritic cells
  • Graft engineering
  • iPSCs
  • pDNA

Marketplace (1)

  • Service

    Global Cell and Gene Therapy CDMO

    Process development, phase 1- commercial manufacturing for Cell Therapy and Gene Therapy.

    • Development
    • Manufacturing
    Author

    Matthew Cobb

    Senior Account Director at Catalent Cell and Gene Therapy

    Cambridge UK, United Kingdom